Quantcast
Last updated on April 17, 2014 at 9:25 EDT

Latest Peptides Stories

2010-09-09 09:17:00

BASKING RIDGE, N.J., Sept. 9 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David J. Mazzo, PhD, President and CEO, will be presenting at the Stifel Nicolaus Healthcare Conference at the Four Seasons Hotel located at 200 Boylston Street in Boston, Massachusetts. Dr. Mazzo's presentation will be given at 2:40 pm EDT in the Winthrop Room and will include an overview of the Company's...

2010-08-05 15:29:38

Phase 3 trials of icatibant show rapid symptom relief with no serious side effects Clinical trials from two international research teams have shown that icatibant, a new drug that blocks the action of an inflammatory protein known as bradykinin, is safe and effective in treating acute attacks of hereditary angioedema, a potentially life-threatening condition. In their report in the August 5 New England Journal of Medicine, the authors note that "“ while the results of one trial did not...

2010-08-02 19:04:36

New research in the FASEB Journal shows that a peptide derived from bee venom can deliver liposomes bearing drugs or diagnostic dyes to specific cells or tissues The next time you are stung by a bee, here's some consolation: a toxic protein in bee venom, when altered, significantly improves the effectiveness liposome-encapsulated drugs or dyes, such as those already used to treat or diagnose cancer. This research, described in the August 2010 print issue of the FASEB Journal...

2010-07-27 09:17:00

BASKING RIDGE, N.J., July 27 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David J. Mazzo, Ph.D., President and CEO, will be presenting at Wedbush Securities Life Sciences Best Ideas MAC: Management Access Conference at the Parker Meridien Hotel in New York City on August 3, 2010. Dr. Mazzo's presentation will be given at 8:00 a.m. EDT in the Lorica Room and will include an...

2010-07-26 15:05:00

BASKING RIDGE, N.J., July 26 /PRNewswire/ -- Regado Biosciences, Inc., a privately held biopharmaceutical company pioneering the development of a novel two-component antithrombotic drug technology consisting of therapeutic aptamers with their matched active control agents, announced publication of results from a Phase 2a study for its lead compound, the REG1 system. The study is known as REVERSAL-PCI. The company's REG1 technology, a selective coagulation factor IXa inhibiting aptamer...

2010-07-22 06:30:00

SAN FRANCISCO, July 22 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a biopharmaceutical company focused on the development of novel therapeutics for cardiovascular disease, today announced the appointment of Richard B. Brewer as Executive Chairman. With over 35 years of biotech and pharmaceutical industry experience, Mr. Brewer brings a wealth of operational, financial, and business development expertise to Nile. "We are extremely pleased to welcome Mr. Brewer to our...

990ab4b029028b7861d71b79a5ef5f021
2010-06-24 08:44:59

A team of Vanderbilt chemists has developed a novel method for chemically synthesizing peptides that promises to lower the cost and increase the availability of drugs based on natural compounds. The new synthesis technique is described in a paper published in the June 24 issue of the journal Nature. Peptides are polymers made by stringing together two or more amino acids, the chemical building blocks of life, in a linear chain and folded into a globular form. DNA holds the blueprints for 20...

3f3e9302d0bc34c22224d878d923b8881
2010-06-21 14:15:00

In a breakthrough, UCI chemists create synthetic antibodies that block bee venom UC Irvine researchers have developed the first "plastic antibodies" successfully employed in live organisms "“ stopping the spread of bee venom through the bloodstream of mice. Tiny polymeric particles "“ just 1/50,000th the width of a human hair "“ were designed to match and encase melittin, a peptide in bee venom that causes cells to rupture, releasing their contents. Large quantities of...

2010-06-17 08:30:00

BASKING RIDGE, N.J., June 17 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David J. Mazzo, PhD, President and CEO, will be presenting at the 2010 Wells Fargo Healthcare Conference at the InterContinental Hotel in Boston, Massachusetts. Dr. Mazzo's presentation will be given at 8:00 am (EDT) on Thursday, June 24 in the Robinson Room and will include an overview of the Company's...

8269a8b716b8ce9ff22b7288634702d01
2010-06-09 10:28:10

Scientists are reporting the first evidence that a plastic antibody "” an artificial version of the proteins produced by the body's immune system to recognize and fight infections and foreign substances "” works in the bloodstream of a living animal. The discovery, they suggest in a report in the Journal of the American Chemical Society, is an advance toward medical use of simple plastic particles custom tailored to fight an array of troublesome "antigens." Those antigens include...